With the American Society of Clinical Oncology Annual Meeting coming to an end, there was a range of abstract presentation highlights for biotech and pharma investors and analysts.
Tazeen Ahmad gives Buy rating to Fatem Incyte and ADC therapeutics
For instance, BoA Securities analyst Tazeen Ahmad highlighted several companies, including Fate Therapeutics (NASDAQ: FATE), Incyte (NASDAQ: INCY), ADC Therapeutics (NYSE: ADCT), and Clovis Oncology (NASDAQ: CLVS), all of which he gave a Buy rating except Clovis.
Ahmad said Incyte’s outstanding data on tafasitamab in relapsed/remitting diffuse large b-cell lymphoma and the phase 2 data on retifanlimab in patients with solid malignancies, including melanoma, renal cell carcinoma, and non-small-cell carcinoma, was impressive.
According to Ahmad, data on Fate’s FT516 in relapsed/refractory B-cell lymphoma combined with lymphoma is promising for use following CAR-T treatments. He noted that overall there is a good assessment of the revised data to believe that the durability of FATE’s [natural killer] therapies is a major topic that has yet to be solved. Ahmad said that they have been waiting for long-term data for indications of persistent responses.
Ahmad feels the safety profile of ADC’s phase 1b camidanlumab tesirine monotherapy for advanced solid tumors supports a potential combination with Keytruda (pembrolizumab).
Clovis releases positive data for rubraca in ovarian cancer
On the other hand, Clovis, which he gave an Underperform rating, released new information about Rubraca (rucaparib) with lucitinib. Whereas the Rubraca result for ovarian cancer was favorable, Ahmad pointed out that the PARP inhibitor industry is very competitive. He further indicated that more data is needed to assess lucitanib’s potential in advanced solid tumors, such as metastatic breast cancer.
H.C. Wainwright’s Aaron Fein reiterated a buy rating for i-Mab (NASDAQ: IMAB) with a price target of $75 following phase 1 uliliedlimab study data that showed efficacy in treating advanced solid tumors.